Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.

IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE
Chest Pub Date : 2025-02-26 DOI:10.1016/j.chest.2025.02.018
Justin M Oldham, Megan L Neely, Daniel M Wojdyla, Mridu Gulati, Peide Li, Divya C Patel, Scott M Palmer, Jamie L Todd
{"title":"Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.","authors":"Justin M Oldham, Megan L Neely, Daniel M Wojdyla, Mridu Gulati, Peide Li, Divya C Patel, Scott M Palmer, Jamie L Todd","doi":"10.1016/j.chest.2025.02.018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with lung function decline and high mortality.</p><p><strong>Research question: </strong>What are the associations between thresholds of lung function decline and the risk of mortality in patients with IPF?</p><p><strong>Study design and methods: </strong>The Idiopathic Pulmonary Fibrosis-Prospective Outcomes Registry enrolled patients with IPF that was diagnosed or confirmed at the enrolling center within the prior 6 months. Associations between time to first decline in FVC or diffusing capacity of the lungs for carbon monoxide (Dlco) of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted (and ≥ 15% predicted for Dlco) and risk of subsequent death or lung transplant was assessed using Cox proportional hazards models with a time-dependent covariate. Models were unadjusted or adjusted for FVC and Dlco % predicted, age, sex, smoking status, BMI, antifibrotic treatment (yes or no), and oxygen use at enrollment.</p><p><strong>Results: </strong>Among 1,001 patients, median follow-up time was 38.4 months. Significant associations were observed between all thresholds of decline in FVC and Dlco % predicted and the risk of death or lung transplant in unadjusted and adjusted analyses. In adjusted analyses, absolute declines in FVC of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted were associated with 1.8-fold, 2.3-fold, and 2.7-fold increases in the risk of subsequent death or lung transplant, whereas absolute declines in Dlco of ≥ 2% predicted, ≥ 5% predicted, ≥ 10% predicted, and ≥ 15% predicted were associated with 2.0-fold, 1.4-fold, 1.5-fold, and 1.9-fold increases in the risk of subsequent death or lung transplantation, respectively. For Dlco, but not FVC, the increase in risk generally was greater for patients meeting a threshold based on a relative rather than an absolute decline.</p><p><strong>Interpretation: </strong>Even small declines in FVC and Dlco % predicted inform prognosis in patients with IPF.</p><p><strong>Clinical trial registry: </strong>ClinicalTrials.gov; No.: NCT01915511; URL: www.</p><p><strong>Clinicaltrials: </strong>gov.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2025.02.018","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with lung function decline and high mortality.

Research question: What are the associations between thresholds of lung function decline and the risk of mortality in patients with IPF?

Study design and methods: The Idiopathic Pulmonary Fibrosis-Prospective Outcomes Registry enrolled patients with IPF that was diagnosed or confirmed at the enrolling center within the prior 6 months. Associations between time to first decline in FVC or diffusing capacity of the lungs for carbon monoxide (Dlco) of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted (and ≥ 15% predicted for Dlco) and risk of subsequent death or lung transplant was assessed using Cox proportional hazards models with a time-dependent covariate. Models were unadjusted or adjusted for FVC and Dlco % predicted, age, sex, smoking status, BMI, antifibrotic treatment (yes or no), and oxygen use at enrollment.

Results: Among 1,001 patients, median follow-up time was 38.4 months. Significant associations were observed between all thresholds of decline in FVC and Dlco % predicted and the risk of death or lung transplant in unadjusted and adjusted analyses. In adjusted analyses, absolute declines in FVC of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted were associated with 1.8-fold, 2.3-fold, and 2.7-fold increases in the risk of subsequent death or lung transplant, whereas absolute declines in Dlco of ≥ 2% predicted, ≥ 5% predicted, ≥ 10% predicted, and ≥ 15% predicted were associated with 2.0-fold, 1.4-fold, 1.5-fold, and 1.9-fold increases in the risk of subsequent death or lung transplantation, respectively. For Dlco, but not FVC, the increase in risk generally was greater for patients meeting a threshold based on a relative rather than an absolute decline.

Interpretation: Even small declines in FVC and Dlco % predicted inform prognosis in patients with IPF.

Clinical trial registry: ClinicalTrials.gov; No.: NCT01915511; URL: www.

Clinicaltrials: gov.

特发性肺纤维化患者肺功能变化及死亡风险
背景:特发性肺纤维化(IPF)是一种进行性纤维化间质性肺疾病,与肺功能下降和高死亡率相关。研究问题:IPF患者肺功能下降阈值与死亡风险之间有何关联?研究设计和方法:特发性肺纤维化-前瞻性结局登记纳入了在前6个月内在入组中心诊断或确诊的IPF患者。使用具有时间相关协变量的Cox比例风险模型评估FVC或肺弥散能力首次下降的预测时间≥2%、预测时间≥5%和预测时间≥10% (Dlco预测时间≥15%)与随后死亡或肺移植风险之间的相关性。模型未调整或调整FVC和Dlco预测百分比、年龄、性别、吸烟状况、BMI、抗纤维化治疗(是否)和入组时的氧气使用。结果:1001例患者中位随访时间为38.4个月。在未调整和调整分析中,观察到FVC和Dlco %预测下降的所有阈值与死亡或肺移植风险之间存在显著关联。在校正分析中,预测FVC绝对下降≥2%、预测≥5%和预测≥10%与随后死亡或肺移植风险增加1.8倍、2.3倍和2.7倍相关,而预测Dlco绝对下降≥2%、预测≥5%、预测≥10%和预测≥15%分别与随后死亡或肺移植风险增加2.0倍、1.4倍、1.5倍和1.9倍相关。对于Dlco,而不是FVC,一般来说,达到基于相对下降而不是绝对下降的阈值的患者风险增加更大。解释:即使FVC和Dlco %的微小下降也能预测IPF患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chest
Chest 医学-呼吸系统
CiteScore
13.70
自引率
3.10%
发文量
3369
审稿时长
15 days
期刊介绍: At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信